Astrazeneca Ab

Lars Sandberg

Karin Kolmodin

Peter Soderman

Sofia Karlstrom

Liselotte Ohberg

Britt-Marie Swahn

Martin Nylöf

Laszlo Rakos

Gabor Csjernyik

Annika Kers

Stefan Von Berg

Fernando Sehgelmeble

Inger Kers

Peter Söderman

Yevgeni Besidski

Karin Skogholm

Sofia Karlström

Liselotte Öhberg

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A&#x3b2;-related pathologies such as Down's syndrome, &#x3b2;-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ('mild cognitive impairment'), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Compounds and their use as BACE inhibitors

2H-imidazol-4-amine compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating A&#x3b2;-related pathologies such as Down's syndrome, &#x3b2;-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. methods of therapy, and pharmaceutical compositions containing such compounds.

2H-imidazol-4-amine compounds and their use as BACE inhibitors

Cyclohexane-1,2'-indene-1&#x2032;,2&#x2033;-imidazole compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating A&#x3b2;-related pathologies such as Down's syndrome, &#x3b2;-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, methods of therapy using such compounds, and pharmaceutical compositions containing such compounds.

Cyclohexane-1,2'-indene-1&#x2032;,2&#x2033;-imidazol compounds and their use as BACE inhibitors

Cyclohexane-1,2'-naphthalene-1&#x2032;,2&#x2033;-imidazole compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating A&#x3b2;-related pathologies such as Down's syndrome, &#x3b2;-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, methods of therapy using such compounds, and pharmaceutical compositions containing such compounds.

Cyclohexane-1,2'-naphthalene-1&#x2032;,2&#x2033;-imidazol compounds and their use as BACE inhibitors

The present invention relates to new compounds of formula (I) and to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. 

N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain

Growing community of inventors

Macclesfield, United Kingdom

Lars Sandberg